Breath test for detecting liver disease
Volatile Organic Compounds for the Assessment of Liver Disease: Assessment of Hepatobiliary Disease Through Non-Invasive Detection of Exhaled Volatile Organic Compounds
Imperial College London · NCT04620538
This study is testing whether a breath test can help find liver diseases early by looking for specific compounds in the breath of patients visiting liver clinics.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT04620538 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of breath analysis to identify volatile organic compounds (VOCs) that may indicate the presence of liver diseases such as fibrosis, cirrhosis, and hepatocellular carcinoma. Patients attending liver outpatient services will provide breath samples, which will be analyzed using multi-platform mass spectrometry to establish a profile of VOCs associated with these conditions. The goal is to develop a non-invasive diagnostic tool that can accurately detect liver disease at an early stage.
Who should consider this trial
Good fit: Ideal candidates include patients aged 18-90 with suspected or confirmed liver or pancreatic disease.
Not a fit: Patients who are unable to provide informed consent or those outside the specified age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a simple and non-invasive method for early detection of serious liver conditions.
How similar studies have performed: Preliminary studies have shown promise in using breath analysis for detecting other cancers, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients seen in secondary care with suspected or confirmed liver / pancreatic disease or hepatocellular carcinoma / pancreatic cancer * Patients able to understand and retain the information provided, thereby being able to give informed consent for inclusion in this study Exclusion Criteria: * Patients who lack capacity or unable to provide informed consent. * Any patient outside the established age range (18-90years). * Patients unable to fast.
Where this trial is running
London
- Imperial College Healthcare Trust — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: George B Hanna, FRCS — Imperial College London
- Study coordinator: Michael J Hewitt, MBBS BSc
- Email: michael.hewitt06@imperial.ac.uk
- Phone: 02033126328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cirrhosis, Cirrhosis, Liver, Fibrosis, Liver, Hepatocellular Carcinoma, Hepatocellular Cancer, Volatile Organic Compound, VOC